An Introduction to Medicinal Chemistry

Häftad, Engelska, 2023

829 kr

Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Medication is widely used to support the human body to fight against infection and pain. In an era of pharmaceutical and medicinal challenges, we have all become more familiar with drug production and distribution. However, do we really know what happens before those drugs are distributed? What's the process behind drug discovery? How do our bodies interact with those chemicals? An Introduction to Medicinal Chemistry, 7th edition, offers a complete and accessible approach to this multidisciplinary field. Its student-friendly writing style makes this text an ideal tool for those coming to the subject for first time, but also for students looking to deepen their understanding.The book guides students through understanding the principles of drug action targets in Part A, to how drugs interact at a molecular level with our organs to offer therapeutic value in Part B, and exploring drug design and discovery, as well as regulatory procedures in Part C. Offering a practical approach, Part D provides a deeper look at specific tools and techniques of medicinal chemistry, concluding with emerging topics including antibodies and anticancer agents in Part E. From principles to practice, accompanied by examples and case studies emerging from current biomedical research, the book will equip students with a robust understanding of medicinal chemistry, to prepare them for future success.

Produktinformation

Utgivningsdatum2023-03-16
Mått221 x 275 x 38 mm
Vikt2 334 g
FormatHäftad
SpråkEngelska
Antal sidor960
Upplaga7
FörlagOUP OXFORD
ISBN9780198866664

Tillhör följande kategorier

Analytisk kemi inom Naturvetenskap och teknik
Farmakologi inom Medicin

Dr Graham L. Patrick gained his BSc Honours at Glasgow University, winning the McKay-Smith Prize for Chemistry. He completed his PhD with Professor Kirby and Professor Robins studying the biosynthesis of gliotoxin and related fungal metabolites. Following this, he worked in the pharmaceutical industry as a research chemist and radiochemist on a variety of projects that included topic areas such as opioids, antibacterial agents and antidepressants. His academic career has included positions at Leeds and Strathclyde Universities as well as the Australian National University. He joined the University of Paisley (now the University of the West of Scotland) in 1990, teaching medicinal chemistry and drug design. Currently, he is an Associate Lecturer with the Open University, an author of scientific textbooks and fiction, and an historical archivist

1: Drugs and Drug Targets 2: Protein Structure and Function 3: Enzymes: Structure and Function 4: Receptors: Structure and Function 5: Receptors and Signal Transduction 6: Nucleic Acids: Structure and Function 7: Enzymes as Drug Targets 8: Receptors as Drug Targets 9: Nucleic Acids as Drug Targets 10: Miscellaneous Drug Targets 11: Pharmacokinetics and Related Topics Case Study 1: Statins 12: Drug Discovery: Finding a Lead 13: Drug Design: Optimizing Target Interactions 14: Drug Design: Optimizing Access to the Target 15: Getting the Drug to Market Case Study 2: The Design of ACE Inhibitors Case Study 3: Artemisinin and Related Antimalarial Drugs Case Study 4: The Design of Oxamni Case Study 5: Fosfidomycin as an Antimalarial Agent 16: Combinatorial and Parallel Synthesis 17: In Silico Drug Design 18: Quantitative Structure-Activity Relationships Case Study 6: De Novo Design of a Thymidylate Synthase Inhibitor 19: Antibacterial Agents 20: Antiviral Agents 21: Anticancer Agents 22: Protein Kinase Inhibitors as Anticancer Agents 23: Antibodies and Other Biologics 24: Cholinergics, Anticholinergics, and Anticholinestarases 25: Drugs Acting on the Adrenergic Nervous System 26: The Opioid Analgesics 27: Anti-Ulcer Agents 28: Cardiovascular Drugs Case Study 7: Steroidal Anti-Inflammatory Agents Case Study 8: Design of a Novel Antidepressant Case Study 9: The Design and Development Of Aliskiren Case Study 10: Factor Xa Inhibitors Case Study 11: Reversible Inhibitors of HCV NS-34A Protease